Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Gains from Investment Securities (2019 - 2025)

Maxcyte (MXCT) has disclosed Gains from Investment Securities for 6 consecutive years, with -$216000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 72.41% to -$216000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $525000.0, a 273.84% increase, with the full-year FY2024 number at $6.9 million, up 12.0% from a year prior.
  • Gains from Investment Securities was -$216000.0 for Q3 2025 at Maxcyte, down from $1.2 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $14.4 million in Q4 2022 to a low of -$783000.0 in Q3 2024.
  • A 5-year average of $818420.6 and a median of $49100.0 in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: soared 6527.18% in 2022, then plummeted 3659.09% in 2024.
  • Maxcyte's Gains from Investment Securities stood at $216700.0 in 2021, then skyrocketed by 6527.18% to $14.4 million in 2022, then crashed by 98.89% to $160000.0 in 2023, then crashed by 349.38% to -$399000.0 in 2024, then soared by 45.86% to -$216000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Gains from Investment Securities are -$216000.0 (Q3 2025), $1.2 million (Q2 2025), and -$47000.0 (Q1 2025).